A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
Key facts
- Where
- Boston and Lutherville, United StatesSee the 2 sites
Where in United States
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- Johns Hopkins University School of MedicineLutherville, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BioSensics
- Trial code
- NCT07569367
- Record updated
- 13 October 2026
- Original description
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.Read full original descriptionShow less
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.
Inclusion: Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype; Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment; Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.
Exclusion: Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment; Individuals who have a history of frequent falls defined as more than 5 falls per month.